Search
Research
Multigenerational disadvantage in AustraliaThis study aims to examine the experience of multiple disadvantages in two generations of Australian families, and how these experiences relate to the trajectories of children, the third generation.
Research
The ORVAC Trial - A phase IV, double-blind, randomised, placebo-controlled clinical trial to optimise the delivery of RV1 rotavirus vaccine to Northern Territory Aboriginal infantsTom Snelling BMBS DTMH GDipClinEpid PhD FRACP Head, Infectious Disease Implementation Research 08 6319 1817 tom.snelling@thekids.org.au Head,
Guide our sibling research!
Research
Tissue resident memory T cells: putting cancer cells to sleep and a target for therapyTissue resident memory T cells are cancer killing immune cells that have emerged as key players in immune-mediated control of solid cancers, as well as being markers of prognosis and predictors of response to immunotherapy.
Research
Tonsil organ model to evaluate carriage, disease mechanisms and therapeutic interventions for treatment and prevention of GAS infectionsTonsil organ model to evaluate carriage, disease mechanisms and therapeutic interventions for treatment and prevention of Group A Streptococcal infections.
Research
Using co-design to understand and enhance the experiences of emerging adults with type 1 diabetes and their parents as they transition from paediatric to adult care in metropolitan and regional Western AustraliaKeely Bebbington MClinPsych/PhD McCusker Postdoctoral Research Fellow in Type 1 Diabetes 08 6319 1766 keely.bebbington@thekids.org.au McCusker
Research
Public health impact of current and proposed age-expanded perennial malaria chemoprevention: a modelling studyIn 2022, the World Health Organization extended their guidelines for perennial malaria chemoprevention (PMC) from infants to children up to 24 months old. However, evidence for PMC's public health impact is primarily limited to children under 15 months. Further research is needed to assess the public health impact and cost-effectiveness of PMC, and the added benefit of further age-expansion. We integrated an individual-based model of malaria with pharmacological models of drug action to address these questions for PMC and a proposed age-expanded schedule (referred as PMC+, for children 03-36 months).
Research
Australian Group on Antimicrobial Resistance surveillance outcome programs - bloodstream infections and antimicrobial resistance patterns in Australian children and adolescents 2022 - 2023Between January 2022 and December 2023, there were 1,827 bloodstream infection (BSI) isolates in 1,745 children and adolescents reported to the Australian Group on Antimicrobial Resistance (AGAR) surveillance outcome programs, with 40% of episodes in children aged < 12 months.
Research
Effectiveness of nirsevimab in preventing RSV-hospitalisation among young children in Western Australia 2024Respiratory Syncytial Virus (RSV) causes a significant burden of illness for children under 2 years of age. Nirsevimab, a long-acting monoclonal antibody, was registered for RSV prevention in Australia in 2023. In April 2024, Western Australia (WA) launched the country's first state-wide nirsevimab program for all infants and high-risk children entering their second RSV season.
Research
Access to Oral Healthcare in Individuals With Rett Syndrome: A Qualitative Study of Parent PerspectivesIntellectual and developmental disabilities (IDD) are varied in their nature and presentation. Barriers to oral healthcare are reported in studies of general populations with IDD but these may not reflect the barriers experienced by individuals with rare disorders such as Rett syndrome.